AU2001294943A1 - Nucleic acid sequences differentially expressed in cancer tissue - Google Patents

Nucleic acid sequences differentially expressed in cancer tissue

Info

Publication number
AU2001294943A1
AU2001294943A1 AU2001294943A AU9494301A AU2001294943A1 AU 2001294943 A1 AU2001294943 A1 AU 2001294943A1 AU 2001294943 A AU2001294943 A AU 2001294943A AU 9494301 A AU9494301 A AU 9494301A AU 2001294943 A1 AU2001294943 A1 AU 2001294943A1
Authority
AU
Australia
Prior art keywords
nucleic acid
acid sequences
differentially expressed
cancer tissue
sequences differentially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294943A
Other languages
English (en)
Inventor
John H. Astle
Christopher Burgess
Eddie Carroll Iii
Theodore J. Catino
Poornima Dwivedi
Marcia E. Lewis
Gary A. Molino
Arunthathi Thiagalingam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of AU2001294943A1 publication Critical patent/AU2001294943A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001294943A 2000-10-02 2001-10-02 Nucleic acid sequences differentially expressed in cancer tissue Abandoned AU2001294943A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23727100P 2000-10-02 2000-10-02
US60/237,271 2000-10-02
PCT/US2001/030732 WO2002029086A2 (en) 2000-10-02 2001-10-02 Nucleic acid sequences differentially expressed in cancer tissue

Publications (1)

Publication Number Publication Date
AU2001294943A1 true AU2001294943A1 (en) 2002-04-15

Family

ID=22893028

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294943A Abandoned AU2001294943A1 (en) 2000-10-02 2001-10-02 Nucleic acid sequences differentially expressed in cancer tissue

Country Status (5)

Country Link
US (2) US20040110668A1 (https=)
EP (1) EP1330543A4 (https=)
JP (2) JP2004528810A (https=)
AU (1) AU2001294943A1 (https=)
WO (1) WO2002029086A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258973B2 (en) * 1998-08-31 2007-08-21 Mayo Foundation For Medical Education & Research Method for detecting a differentially expressed sequence
EP1666594A3 (en) * 2000-06-02 2006-06-21 Genentech, Inc. Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP2330221A1 (en) * 2001-09-14 2011-06-08 Clinical Genomics Pty. Ltd Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma
US7449548B2 (en) 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
EP2275118A3 (en) 2002-05-29 2011-10-19 DeveloGen Aktiengesellschaft Pancreas-specific proteins
AU2003245488A1 (en) * 2002-06-13 2003-12-31 Regulome Corporation Functional sites
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US7393950B2 (en) * 2002-08-29 2008-07-01 Hong Kong University Of Science & Technology Antisense oligonucleotides targeted to human CDC45
US7749695B2 (en) * 2003-03-03 2010-07-06 Alexander Abbas PRO polypeptides for diagnosis of systemic lupus erythematosis
WO2005017102A2 (en) * 2003-05-30 2005-02-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
DE10332854A1 (de) * 2003-07-18 2005-02-17 Universitätsklinikum der Charité der Humboldt-Universität zu Berlin Verwendung des neu-identifizierten humanen Gens 7a5/Prognostin für Tumordiagnostik und Tumortherapie
EP2311468B1 (en) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US20060134653A1 (en) * 2004-07-28 2006-06-22 Bayer Healthcare Llc Differential expression of genes in microsatellite instability
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
FR2919061B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
JP5715817B2 (ja) * 2007-07-19 2015-05-13 ビオメリューＢｉｏｍｅｒｉｅｕｘ 結腸直腸癌のインビトロ診断のための肝臓脂肪酸結合タンパク質、ｃｅａおよびｃａ１９−９のアッセイのための方法
FR2919060B1 (fr) * 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919064B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919063B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
WO2010135786A1 (en) * 2009-05-29 2010-12-02 Clinical Genomics Pty. Ltd. A method for diagnosing neoplasms and molecules for use therein
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
US11136583B2 (en) 2017-01-10 2021-10-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
JP6702932B2 (ja) * 2017-12-27 2020-06-03 富士フイルム株式会社 細胞撮像制御装置および方法並びにプログラム

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024513A1 (en) * 1992-05-22 1993-12-09 The Children's Hospital Of Philadelphia Gastrointestinal defensins, cdna sequences and method for the production and use thereof
US5861494A (en) * 1995-06-06 1999-01-19 Human Genome Sciences, Inc. Colon specific gene and protein
US6171816B1 (en) * 1996-08-23 2001-01-09 Human Genome Sciences, Inc. Human XAG-1 polynucleotides and polypeptides
US5837841A (en) * 1996-10-11 1998-11-17 Incyte Pharmaceuticals, Inc. Human Reg protein
WO1999010363A1 (en) * 1997-08-29 1999-03-04 Human Genome Sciences, Inc. 29 human secreted proteins
WO1998041627A1 (en) * 1997-03-19 1998-09-24 Zymogenetics, Inc. Secreted polypeptides with homology to xenopus cement gland proteins
AU1726199A (en) * 1997-12-31 1999-07-19 Chiron Corporation Metastatic cancer regulated gene
US5929033A (en) * 1998-02-10 1999-07-27 Incyte Pharmaceuticals, Inc. Extracellular mucous matrix glycoprotein
DE19817946A1 (de) * 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
US6262333B1 (en) * 1998-06-10 2001-07-17 Bayer Corporation Human genes and gene expression products
EP1108021A2 (en) * 1998-08-31 2001-06-20 Bayer Corporation Human genes differentially expressed in colorectal cancer
EP1144632A3 (en) * 1998-12-23 2001-11-07 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2001070979A2 (en) * 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer

Also Published As

Publication number Publication date
EP1330543A2 (en) 2003-07-30
WO2002029086A3 (en) 2002-10-03
JP2004528810A (ja) 2004-09-24
EP1330543A4 (en) 2006-03-29
US20060179496A1 (en) 2006-08-10
US20040110668A1 (en) 2004-06-10
WO2002029086A2 (en) 2002-04-11
JP2007289196A (ja) 2007-11-08

Similar Documents

Publication Publication Date Title
AU2001294943A1 (en) Nucleic acid sequences differentially expressed in cancer tissue
AU7680300A (en) Human dna sequences
AU2002211313A1 (en) Gene expression profiles in liver cancer
AU2001295732A1 (en) Concatenated nucleic acid sequences
AU3316600A (en) Gene expression in bladder tumors
AU2002352799A1 (en) Methods for evaluating drug-resistance gene expression in the cancer patient
AU1922301A (en) Differential gene expression in cancer
AU5691699A (en) Human genes differentially expressed in colorectal cancer
AU2001266225A1 (en) Decondensation of dna
AU2001242625A1 (en) Gene sequence
AU3605901A (en) Nucleic acid sequences showing enhanced expression in benign neuroblastoma compared with acritical human neuroblastoma
AU2001295841A1 (en) Human dna sequences
AU8026300A (en) Sodd gene expression in cancer
AU2001270478A1 (en) Gene expression in biological conditions
AU2001240103A1 (en) Reproduction-specific genes
AU2001292472A1 (en) Rf connector
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2001285257A1 (en) Human telomerase rna elements
AU2001257427A1 (en) Rna metabolism proteins
AU2001285743A1 (en) Adipose-related gene
AU5416700A (en) Differentially expressed genes in prostate cancer
AU2002364077A1 (en) Gene expression profiles in stomach cancer
AU2002324790A1 (en) Transmembrane protein differentially expressed in cancer
AU2001268466A1 (en) 55p4h4: gene expressed in various cancers
AU6529000A (en) Dna sequences isolated from human colonic epithelial cells